Merck's Fake MMR Trial Results Buried Even As Measles Scare Shows Vaccine Surge

By R. Siva Kumar - 26 Jan '15 09:32AM
Close

The vaccine industry piggybacks on the Measles scare at Disneyland to call for MMR vaccinations. But  there is silence on Big Pharma faking the MMR vaccine clinical trial results a few years ago.

In 2010, two Merck scientists filed a False Claims Act complaint that was unsealed three years ago. The vaccine manufacturer, Merck, falsified its mumps vaccine test data even though it was aware of it. It "spiked blood samples with animal antibodies, sold a vaccine that actually promoted mumps and measles outbreaks, and ripped off governments and consumers who bought the vaccine thinking it was 95% effective," according to naturalnews.com.

Natural News claims that it obtained all the records some years ago. It has continued to retain one of its  crucial copies, even while "official" sources try to eliminate it from existence.

Read the full document here.

According to Stephen Krahling and Joan Wlochowski, who were the earlier Merck virologists that filed the charge, this is what the company did:

The company deliberately falsified its mumps vaccine test results in order to get an efficacy rate that was 95%. For this, Merck "spiked" a blood sample with animal antibodies in order to "inflate" the appearance of the immune system antibodies.

As CourthouseNews.com reported: "Merck also added animal antibodies to blood samples to achieve more favorable test results, though it knew that the human immune system would never produce such antibodies, and that the antibodies created a laboratory testing scenario that did not in any way correspond to, correlate with, or represent real life ... virus neutralization in vaccinated people," according to the complaint.

The company then used the fake conclusions in order to cheat the US government of "hundreds of millions of dollars for a vaccine that does not provide adequate immunization."

It has led to continued mumps throughout the US, infecting a lot of kids with the disease. The vaccine has spread the disease.

The "95 percent effectiveness" was used by Merck in order to dominated the market for vaccinations and remove the competitors.

This fraud has been on since the later part of the 1990s, confirm the Merck virologists. The vaccines were never tested against the "real-world" mumps viruses, but the results were just doctored in order to arrive at this result. It was a deceit that got the complete approval of the company's senior management.

The company's researchers witnessed the "improper testing and data falsification". Instead of taking appropriate reaction on this "false claims act", the government simply did not bother about it. Hence, it protected the company's dictatorial monopoly, and also showed the "conspiracy of fraud" between the government, FDA regulators as well as the company.

Once the 2010 False Claims Act was open, Chatom Primary Care, based in Alabama, understood what was wrong. In 2012, Chatom filed a lawsuit against Merck. Check the record here.

The document explains that Merck got involved in a long scheme to misrepresent the vaccination. The company wrongly represented that the Mumps Vaccine has an efficacy rate of 95 percent or higher.

In fact, the company had a testing methodology to test its vaccine opposing a lower strain of the mumps virus. But as it did not get the desired efficacy, Merck dunked the methods and did not reveal the results.

Every year, thousands of children are not getting protection from mumps.Even though this disease should have been wiped out, according to the Centers for Disease Control ('CDC'), the failure of Merck's vaccine continues to let the epidemic rage everywhere.

Moreover, Chatom Primary Care points out that the fraudulent Merck vaccine led to the 2006 mumps outbreak in the Midwest, and a 2009 rash elsewhere. "There has remained a significant risk of a resurgence of mumps outbreaks...," feels Merck.

Fun Stuff

3
4 Products Moms Can't Live Without

4 Products Moms Can't Live Without

11 Mar '21 14:01PM

Join the Conversation

The Next Read

Real Time Analytics